Lee, Hye Jin Shin, Seungho Kang, Jinho Han, Ki-Cheol Kim, Yeul Hong Bae, Jeoung-Won Park, Kyong Hwa 2024-01-19T16:34:43Z 2024-01-19T16:34:43Z 2021-09-02 2020-09 2072-6694 https://pubs.kist.re.kr/handle/201004/118194 Simple Summary Lapatinib is a tyrosine kinase inhibitor widely used as a treatment for a Human Epidermal growth factor Receptor 2 (HER2) (+) breast cancer patients. However, when resistance is acquired through continued exposure, and it is associated with a poor prognosis for patients. In this study, we identified HSP90 as a common node for acquired resistance to lapatinib in two lapatinib resistant cell lines using proteomic analysis. Notably, in vitro and in vivo studies demonstrated synergy effect between lapatinib and an HSP90 inhibitor were observed in the estrogen receptor (+) HER2 (+) breast cancer cell only. These results could be a potential strategy for future clinical trials for HSP90 inhibitors in treatment-refractory HER2 (+) metastatic cancer patients Lapatinib, a Human Epidermal growth factor Receptor 2 (HER2)-targeting therapy in HER2-overexpressing breast cancer, has been widely used clinically, but the prognosis is still poor because most patients acquire resistance. Therefore, we investigated mechanisms related to lapatinib resistance to evaluate new therapeutic targets that may overcome resistance. Lapatinib-resistant cell lines were established using SKBR3 and BT474 cells. We evaluated cell viability and cell signal changes, gene expression and protein changes. In the xenograft mouse model, anti-tumor effects were evaluated using drugs. Analysis of the protein interaction network in two resistant cell lines with different lapatinib resistance mechanisms showed that HSP90 protein was commonly increased. When Heat Shock Protein 90 (HSP90) inhibitors were administered alone to both resistant cell lines, cell proliferation and protein expression were effectively inhibited. However, inhibition of cell proliferation and protein expression with a combination of lapatinib and HSP90 inhibitors showed a more synergistic effect in the LR-BT474 cell line than the LR-SKBR3 cell line, and the same result was exhibited with the xenograft model. These results suggest that HSP90 inhibitors in patients with lapatinib-resistant Estrogen Receptor (ER) (+) HER2 (+) breast cancer are promising therapeutics for future clinical trials. English MDPI SHOCK-PROTEIN 90 GROWTH-FACTOR RECEPTOR PHASE-II TRASTUZUMAB RESISTANCE TANESPIMYCIN 17-AAG PLUS TRASTUZUMAB UP-REGULATION OPEN-LABEL GANETESPIB DOCETAXEL HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line Article 10.3390/cancers12092630 1 CANCERS, v.12, no.9 CANCERS 12 9 scie scopus 000580771000001 2-s2.0-85090894237 Oncology Oncology Article SHOCK-PROTEIN 90 GROWTH-FACTOR RECEPTOR PHASE-II TRASTUZUMAB RESISTANCE TANESPIMYCIN 17-AAG PLUS TRASTUZUMAB UP-REGULATION OPEN-LABEL GANETESPIB DOCETAXEL breast cancer ER (+) HER2 (+) lapatinib resistance HSP90